Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile
Lifecore Biomedical - Stock

Lifecore Biomedical Stock

LFCR
US5147661046
899376

Price

4.89
Today +/-
+0
Today %
+0 %
P

Lifecore Biomedical Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Lifecore Biomedical, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Lifecore Biomedical from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Lifecore Biomedical’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Lifecore Biomedical. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Lifecore Biomedical’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Lifecore Biomedical’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Lifecore Biomedical’s growth potential.

Lifecore Biomedical Revenue, EBIT and net profit per share

DateLifecore Biomedical RevenueLifecore Biomedical EBITLifecore Biomedical Net Income
2026e167.59 M undefined21.49 M undefined-3.74 M undefined
2026e164.55 M undefined22.71 M undefined2.8 M undefined
2025e147.59 M undefined22.34 M undefined-13.4 M undefined
2024e127.91 M undefined3.32 M undefined-23.68 M undefined
2023103.27 M undefined-19.72 M undefined-99.56 M undefined
2022185.8 M undefined-3.5 M undefined-114.7 M undefined
2021171.5 M undefined5.4 M undefined-32.7 M undefined
2020160.1 M undefined-8.9 M undefined-38.2 M undefined
2019557.6 M undefined10.8 M undefined400,000 undefined
2018524.2 M undefined13.6 M undefined24.8 M undefined
2017469.8 M undefined17.2 M undefined10.6 M undefined
2016476.9 M undefined13.4 M undefined-11.6 M undefined
2015539.3 M undefined18.5 M undefined13.5 M undefined
2014476.8 M undefined20.2 M undefined19.1 M undefined
2013441.7 M undefined24.9 M undefined22.6 M undefined
2012317.6 M undefined14.6 M undefined12.7 M undefined
2011276.7 M undefined8 M undefined3.9 M undefined
2010238.2 M undefined8 M undefined4 M undefined
2009235.9 M undefined12.6 M undefined7.7 M undefined
2008238.5 M undefined15.2 M undefined13.5 M undefined
2007210.5 M undefined7.7 M undefined29.2 M undefined
2006232 M undefined9 M undefined8.7 M undefined
2005205.2 M undefined6 M undefined5.4 M undefined
2004192.1 M undefined4.1 M undefined2.4 M undefined

Lifecore Biomedical Stock Ratios

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
199119921993199419951996199719981999200020012002200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2026e
01113221821197190183192205232210238235238276317441476539476469524557160171185103127147164167
----200.00-33.33-800.0016.67838.10-3.55-3.684.926.7713.17-9.4813.33-1.261.2815.9714.8639.127.9413.24-11.69-1.4711.736.30-71.276.888.19-44.3223.3015.7511.561.83
-100.00100.00100.00100.0050.0050.0044.4442.8615.2314.2116.9415.1015.6117.2415.2415.9714.4713.8716.6716.4014.0613.0312.0613.8716.8414.8914.5424.3829.2427.0326.21----
01113118930273129324032383433465262626566797881395050270000
-2-2-3-2-1-4-6-4-30-2146971512881424201813171310-85-3-193222221
--200.00-300.00-200.00-33.33-200.00-300.00-22.22-14.29--1.050.552.082.933.883.336.305.113.362.904.425.444.203.342.733.622.481.80-5.002.92-1.62-18.452.3614.9713.4112.57
-2-2-4-4-2-4-8-2-2-4-7-1258291374312221913-1110240-38-32-114-99-23-132-3
--100.00--50.00100.00100.00-75.00-100.0075.00-85.71-300.00150.0060.00262.50-55.17-46.15-42.86-25.00300.0083.33-13.64-31.58-184.62-190.91140.00---15.79256.25-13.16-76.77-43.48-115.38-250.00
7.77.77.77.71.27.711.112.813.315.816.418.223.624.625.726.626.926.826.626.626.126.627.127.32727.727.928.629.229.329.529.960000
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Lifecore Biomedical Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Lifecore Biomedical is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Lifecore Biomedical provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Lifecore Biomedical's financial health and stability.

Assets

Lifecore Biomedical's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Lifecore Biomedical must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Lifecore Biomedical after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Lifecore Biomedical's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
199319941995199619971998199920002001200220042005200620072008200920102011201220132014201520162017201820192020202120222023
-4-40-2-7-2-3-4-7-1258291384413221913-1110240-38-32-114-102
0000121553333333355777910121518191713
0000000000000002333654-92-70-5-7-60
00000-1-22-110-141-100-2-4-28-303-31-10-1-278-622
00-1-1100-29-220-2-240016-6-9-803984437308835
000000012100000000011122251013160
0000000000000101000500220-1-1-700
-3-3-2-3-5-3-30-4071310-21797142221212620291916-1715-24-34
0000-1-40-3-6-2-3-3-4-6-4-4-5-6-5-8-14-17-39-23-33-44-26-23-28-20
0-31-20540-10-770-5-541-20-12-42-29-44-10-13-34-40-25-35-96-23-1081-4
1-31-20780-6092-1048-15-7-37-22-38-11-160-2-2-5221210916
000000000000000000000000000000
000002066-15-4-5-170019-339-14-9815-71879417-5519
120135010957053-4-1800-1-4320000000042
120234-9301611-8-4-122-15119-435-19-7715-8137940-3-5756
0000-800000000021001-8000-1-5-1-1-10-1-6
000000000000000000000000000000
9-7110-94-260026742-180-15-1914-800-4-4-2-100017
-4.49-3.98-2.29-4.01-6.84-7.45-4.69-3.16-11.07-2.424.129.396.12-9.2413.284.862.297.7916.8112.356.169.11-18.946.84-13.81-28.71-43.73-8.75-52.53-55.22
000000000000000000000000000000

Lifecore Biomedical stock margins

The Lifecore Biomedical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Lifecore Biomedical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Lifecore Biomedical.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Lifecore Biomedical's sales revenue. A higher gross margin percentage indicates that the Lifecore Biomedical retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Lifecore Biomedical's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Lifecore Biomedical's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Lifecore Biomedical's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Lifecore Biomedical. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Lifecore Biomedical's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Lifecore Biomedical Margin History

Lifecore Biomedical Gross marginLifecore Biomedical Profit marginLifecore Biomedical EBIT marginLifecore Biomedical Profit margin
2026e27.1 %12.82 %-2.23 %
2026e27.1 %13.8 %1.7 %
2025e27.1 %15.14 %-9.08 %
2024e27.1 %2.6 %-18.51 %
202327.1 %-19.1 %-96.41 %
202227.13 %-1.88 %-61.73 %
202129.45 %3.15 %-19.07 %
202024.61 %-5.56 %-23.86 %
201914.53 %1.94 %0.07 %
201814.94 %2.59 %4.73 %
201716.86 %3.66 %2.26 %
201614.01 %2.81 %-2.43 %
201512.13 %3.43 %2.5 %
201413.13 %4.24 %4.01 %
201314.22 %5.64 %5.12 %
201216.4 %4.6 %4 %
201116.88 %2.89 %1.41 %
201014.19 %3.36 %1.68 %
200914.54 %5.34 %3.26 %
200816.02 %6.37 %5.66 %
200715.39 %3.66 %13.87 %
200617.24 %3.88 %3.75 %
200515.59 %2.92 %2.63 %
200415.51 %2.13 %1.25 %

Lifecore Biomedical Stock Sales Revenue, EBIT, Earnings per Share

The Lifecore Biomedical earnings per share therefore indicates how much revenue Lifecore Biomedical has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Lifecore Biomedical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Lifecore Biomedical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Lifecore Biomedical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Lifecore Biomedical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Lifecore Biomedical Revenue, EBIT and net profit per share

DateLifecore Biomedical Sales per ShareLifecore Biomedical EBIT per shareLifecore Biomedical Earnings per Share
2026e5.49 undefined0 undefined-0.12 undefined
2026e5.39 undefined0 undefined0.09 undefined
2025e4.83 undefined0 undefined-0.44 undefined
2024e4.19 undefined0 undefined-0.78 undefined
20233.45 undefined-0.66 undefined-3.32 undefined
20226.3 undefined-0.12 undefined-3.89 undefined
20215.85 undefined0.18 undefined-1.12 undefined
20205.48 undefined-0.3 undefined-1.31 undefined
201919.5 undefined0.38 undefined0.01 undefined
201818.79 undefined0.49 undefined0.89 undefined
201716.96 undefined0.62 undefined0.38 undefined
201617.66 undefined0.5 undefined-0.43 undefined
201519.75 undefined0.68 undefined0.49 undefined
201417.59 undefined0.75 undefined0.7 undefined
201316.61 undefined0.94 undefined0.85 undefined
201212.17 undefined0.56 undefined0.49 undefined
201110.4 undefined0.3 undefined0.15 undefined
20108.95 undefined0.3 undefined0.15 undefined
20098.8 undefined0.47 undefined0.29 undefined
20088.87 undefined0.57 undefined0.5 undefined
20077.91 undefined0.29 undefined1.1 undefined
20069.03 undefined0.35 undefined0.34 undefined
20058.34 undefined0.24 undefined0.22 undefined
20048.14 undefined0.17 undefined0.1 undefined

Lifecore Biomedical business model

Landec Corp is a US-American company specialized in the development, manufacturing, and marketing of innovative products in the Agribusiness and Biotechnology sectors. It was founded in 1986 as a spin-off from the engineering faculty of Stanford University. The company follows a unique business model based on the integration of advanced technologies and biological processes. This aims to achieve sustainable agriculture that is both mindful of natural resources and achieves high yields. One of Landec's main divisions is the Fresh-Cut Products segment, where the company produces a variety of high-quality salads, vegetable, and fruit snacks that are distributed under the brand Eat Smart®. These products are known for their freshness, taste, and healthy nutritional values, and have gained high recognition in the USA. Another important business division of Landec is the Apio Packaging segment, specialized in the manufacturing and marketing of innovative packaging solutions for fresh fruits and vegetables. The packaging, distributed under the brand BreatheWay®, is equipped with a unique technology that regulates gas exchange within the package and extends the shelf life of the contents. In addition to these core segments, Landec is also active in the field of Biotechnology. Here, the company develops innovative products and technologies for use in human healthcare as well as the agricultural industry. An example of this is Apio's recently introduced whole plant juice called GreenWise™. Landec Corp is known for its innovation capabilities and its ability to develop new products and technologies. Throughout its history, the company has acquired a number of patents and awards and constantly strives to improve and advance its products. Overall, Landec Corp is a company that focuses on sustainability, innovation, and quality. With its unique business model and wide range of products and services, the company is well-positioned to continue growing and expanding its leadership position in the agriculture and biotechnology industry. Lifecore Biomedical is one of the most popular companies on Eulerpool.com.

Lifecore Biomedical SWOT Analysis

Strengths

1. Strong market presence and well-established brand reputation.

2. Diversified product portfolio across different industries.

3. Robust research and development capabilities, leading to innovative and high-quality products.

Weaknesses

1. Reliance on a few major customers, making the company vulnerable to their changing demands or loss of contracts.

2. Limited geographic presence, mainly operating within specific regions.

3. Higher production costs compared to some competitors.

Opportunities

1. Growing demand for environmentally friendly products, providing an opportunity for the company's sustainable packaging solutions.

2. Expansion into new markets and industries, leveraging existing expertise and capabilities.

3. Acquisition or partnership opportunities to enhance product offerings or access new distribution channels.

Threats

1. Intense competition from both established players and new entrants in the industry.

2. Economic downturns or fluctuations in the market affecting consumer spending patterns.

3. Increasing regulations and compliance requirements impacting product development and manufacturing processes.

Lifecore Biomedical valuation based on historical P/E ratio, EBIT, and P/S ratio.

Lifecore Biomedical shares outstanding

The number of shares was Lifecore Biomedical in 2023 — This indicates how many shares 29.958 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Lifecore Biomedical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Lifecore Biomedical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Lifecore Biomedical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Lifecore Biomedical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Lifecore Biomedical.

Lifecore Biomedical Earnings Surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2023-0.38 -0.89  (-132.68 %)2023 Q4
3/31/2023-0.13 -0.22  (-65.91 %)2023 Q3
12/31/2022-0.04 -0.24  (-488.24 %)2023 Q2
9/30/2022-0.14 -0.32  (-132.39 %)2023 Q1
6/30/2022-0.01 -0.01  (26.47 %)2022 Q4
3/31/2022-0.01 -0.08  (-1,468.63 %)2022 Q3
12/31/2021-0.04 0.05  (222.55 %)2022 Q2
9/30/2021-0.12 -0.23  (-94.42 %)2022 Q1
6/30/2021-0.01 0.07  (953.66 %)2021 Q4
3/31/20210.02 -0.09  (-467.35 %)2021 Q3
1
2
3
4
5
...
8

Eulerpool ESG Scorecard© for the Lifecore Biomedical stock

Eulerpool World ESG Rating (EESG©)

64/ 100

🌱 Environment

45

👫 Social

99

🏛️ Governance

47

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
✅
Hazardous substances
❌
Fuel consumption and efficiency
✅
Water consumption and efficiency
✅

Social

Percentage of female employees48
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

Kontaktformular an uns. The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Lifecore Biomedical Stock Shareholders

%
Name
Stocks
Change
Date
9.62 % Legion Partners Asset Management, LLC2,940,34001/3/2024
7.75 % Greenhaven Road Investment Management, L.P.2,366,956173,62312/31/2023
5.75 % 22NW, LP1,755,16101/6/2024
5.17 % Laughing Water Capital, LP1,578,1971,578,19712/31/2023
4.42 % The Vanguard Group, Inc.1,350,567012/31/2023
3.95 % 325 Capital LLC1,206,9691,206,96912/31/2023
2.98 % Cove Street Capital, LLC910,264-195,29212/31/2023
16.12 % Wynnefield Capital, Inc.4,923,545012/31/2023
1.97 % Morgan Stanley & Co. LLC602,5978,94512/31/2023
1.63 % Visionary Wealth Advisors, LLC497,204-4,13012/31/2023
1
2
3
4
5
...
10

Lifecore Biomedical Executives and Management Board

Mr. James Hall59
Lifecore Biomedical President, Chief Executive Officer, Director (since 2017)
Compensation 913,028
Mr. John Morberg58
Lifecore Biomedical Chief Financial Officer, Company Secretary
Compensation 618,031
Mr. Craig Barbarosh
Lifecore Biomedical Non-Executive Independent Chairman of the Board
Compensation 255,000
Ms. Katrina Houde64
Lifecore Biomedical Independent Director
Compensation 185,000
Mr. Jeffrey Edwards62
Lifecore Biomedical Independent Director
Compensation 183,333
1
2

Lifecore Biomedical stock: Frequently Asked Questions

What values and corporate philosophy does Lifecore Biomedical represent?

Landec Corp represents a set of core values and a corporate philosophy focused on innovation, sustainability, and growth. The company prioritizes delivering innovative solutions and products that address the evolving needs of its customers. Landec Corp aims to contribute positively to the environment and society by employing sustainable practices across its operations. It actively invests in research and development to stay at the forefront of technology advancements, fostering growth opportunities. Through its commitment to operational excellence and customer satisfaction, Landec Corp strives to establish itself as a trusted leader in its industry.

In which countries and regions is Lifecore Biomedical primarily present?

Landec Corp is primarily present in the United States.

What significant milestones has the company Lifecore Biomedical achieved?

Landec Corp has achieved several significant milestones throughout its history. One notable milestone was the acquisition of Lifecore Biomedical in 2013, which expanded their presence in the healthcare industry. Another important achievement was the introduction of the patented BreatheWay technology, which extended the shelf life of fresh produce. In addition, Landec Corp has successfully established strategic partnerships with major retailers, such as Walmart and Whole Foods, further enhancing their market reach. These accomplishments have solidified Landec Corp's position as a leading player in the technology-driven food and biomedical markets.

What is the history and background of the company Lifecore Biomedical?

Landec Corp is a renowned company with a rich history and background. Founded in 1986, Landec Corp has grown to become a leading lifesciences company specializing in innovative health and wellness solutions. With headquarters in Menlo Park, California, Landec Corp focuses on the development and commercialization of differentiated products in various industries. The company is dedicated to solving challenges in agriculture, food, and biomedical materials through its proprietary technologies. Landec Corp has built a strong reputation for delivering high-quality, sustainable products, and its commitment to innovation has propelled its growth and success in the market.

Who are the main competitors of Lifecore Biomedical in the market?

The main competitors of Landec Corp in the market include companies such as Archer-Daniels-Midland Company, Cargill Incorporated, and Ingredion Incorporated.

In which industries is Lifecore Biomedical primarily active?

Landec Corp is primarily active in the food packaging and biomaterial industries.

What is the business model of Lifecore Biomedical?

The business model of Landec Corp revolves around developing and commercializing innovative health and wellness solutions. Landec Corp primarily focuses on creating and selling differentiated products through two business segments: Curation Foods and Lifecore Biomedical. Curation Foods offers a wide range of plant-based foods, such as fresh packaged salads, vegetables, and fruit snacks, while Lifecore Biomedical specializes in developing and manufacturing various biomaterials and products for medical applications. With a commitment to sustainability and healthy living, Landec Corp aims to provide customers with high-quality, environmentally friendly products that enhance overall well-being.

What is the P/E ratio of Lifecore Biomedical 2024?

The Lifecore Biomedical P/E ratio is -6.19.

What is the P/S ratio of Lifecore Biomedical 2024?

The Lifecore Biomedical P/S ratio is 1.15.

What is the AlleAktien quality score of Lifecore Biomedical?

The AlleAktien quality score for Lifecore Biomedical is 3/10.

What is the revenue of Lifecore Biomedical 2024?

The expected Lifecore Biomedical revenue is 127.91 M USD.

How high is the profit of Lifecore Biomedical 2024?

The expected Lifecore Biomedical profit is -23.68 M USD.

What is the business model of Lifecore Biomedical

Landec Corporation is a company specialized in the development and marketing of innovative and sustainable products in various areas. Its main divisions are Lifecore Biomedical and Curation Foods. Lifecore Biomedical produces medical devices and technologies for the field of regenerative medicine, such as implants, artificial joints, and other medical instruments. These products are developed and manufactured in collaboration with medical professionals, using advanced materials and technologies. On the other hand, Curation Foods operates in the food industry, offering different types of fruits and vegetables produced in a healthy and sustainable way. Some of Landec Corp's products include "Eat Smart" products from Curation Foods, which offer various vegetable and fruit salads as well as ready-to-eat meals. The company combines sustainable agriculture, modern processing methods, and innovative packaging design. Another product is IntelliBond, a special micronutrient additive for animal feed. Through patented technology, IntelliBond is designed to be better absorbed by animals, effectively preventing nutrient deficiencies. Landec Corp's business model aims to develop and market sustainable products that improve the health of people and animals while preserving the environment. The company emphasizes close collaboration between scientists, technology experts, and other professionals to develop innovative solutions tailored to the needs of customers and consumers. In addition, the company strives to integrate sustainability principles into its production and supply chains to reduce environmental impacts and conserve resources. This includes the use of recyclable materials and the promotion of projects to improve agriculture and environmental protection. Overall, Landec Corp offers a wide range of innovative and sustainable products in various sectors, focusing on the needs of customers and consumers. The company values sustainability, quality, and innovation, and relies on close collaboration among professionals from different fields to develop sustainable solutions.

What is the Lifecore Biomedical dividend?

Lifecore Biomedical pays a dividend of 0 USD distributed over payouts per year.

How often does Lifecore Biomedical pay dividends?

The dividend cannot currently be calculated for Lifecore Biomedical or the company does not pay out a dividend.

What is the Lifecore Biomedical ISIN?

The ISIN of Lifecore Biomedical is US5147661046.

What is the Lifecore Biomedical WKN?

The WKN of Lifecore Biomedical is 899376.

What is the Lifecore Biomedical ticker?

The ticker of Lifecore Biomedical is LFCR.

How much dividend does Lifecore Biomedical pay?

Over the past 12 months, Lifecore Biomedical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Lifecore Biomedical is expected to pay a dividend of 0 USD.

What is the dividend yield of Lifecore Biomedical?

The current dividend yield of Lifecore Biomedical is .

When does Lifecore Biomedical pay dividends?

Lifecore Biomedical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Lifecore Biomedical?

Lifecore Biomedical paid dividends every year for the past 0 years.

What is the dividend of Lifecore Biomedical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Lifecore Biomedical located?

Lifecore Biomedical is assigned to the 'Non-cyclical consumption' sector.

Wann musste ich die Aktien von Lifecore Biomedical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Lifecore Biomedical from 7/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/7/2024.

When did Lifecore Biomedical pay the last dividend?

The last dividend was paid out on 7/7/2024.

What was the dividend of Lifecore Biomedical in the year 2023?

In the year 2023, Lifecore Biomedical distributed 0 USD as dividends.

In which currency does Lifecore Biomedical pay out the dividend?

The dividends of Lifecore Biomedical are distributed in USD.

Other fundamentals and analyses of Lifecore Biomedical in the deep dive.

Our stock analysis for Lifecore Biomedical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lifecore Biomedical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.